Drugs in Context最新文献

{"title":"Use of safinamide for treatment of Parkinson disease: real-world data from Spain.","authors":"María Isabel Morales Casado, Nuria López Ariztegui","doi":"10.7573/dic.2025-5-5","DOIUrl":"https://doi.org/10.7573/dic.2025-5-5","url":null,"abstract":"<p><p>Safinamide is a monoamine oxidase B inhibitor that was approved in Europe in February 2015 to complement a stable dose of levodopa in monotherapy or in combination with other antiparkinsonian agents in adults affected by mid-stage or advanced Parkinson disease (PD) with fluctuations. It is characterized by a dual mechanism of action (dopaminergic and non-dopaminergic), thus enabling an innovative approach in the management of motor and non-motor symptoms. The safety and efficacy profile of safinamide was previously shown in placebo-controlled randomized clinical trials, which demonstrated that ON time could be increased without the onset of dyskinesia and that OFF time could be decreased, with an improvement in PD. However, the strict inclusion and exclusion criteria in these studies meant that not all patients seen in daily clinical practice were represented, hence the importance of observational studies that evaluate the drug in these situations. The objective of the present article was to collect and review reports from Spanish authors presented at national and international conferences on the use of safinamide in patients with PD. We reviewed a total of 36 reports covering around 2000 patients with PD. The reports confirm the safety and efficacy results obtained in clinical trials, showing a significant improvement in motor and non-motor fluctuations and enabling the dose of levodopa to be reduced, thus decreasing the likelihood of motor complications.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.","authors":"Sarah L Anderson","doi":"10.7573/dic.2025-4-8","DOIUrl":"https://doi.org/10.7573/dic.2025-4-8","url":null,"abstract":"<p><p>The global rise in obesity and its associated health risks has driven the need for more effective pharmacological treatments. Glucagon receptor (GCGR)-based multi-agonist drugs are emerging as promising treatments for obesity, with several in advanced stages of clinical development. Agents like mazdutide, pemvidutide, survodutide and retatrutide have demonstrated the ability to trigger significant weight loss in earlier phase trials, often surpassing the amount of weight loss obtained with existing therapies. Their potential to address obesity-related comorbidities, including type 2 diabetes mellitus and cardiovascular disease, positions them as important additions to future obesity treatment guidelines. As these GCGR-based multi-agonists advance through clinical trials, their impact on obesity management may be substantial, particularly for patients who have not achieved success with current medications or lifestyle interventions. Some are also being evaluated for cardiovascular outcomes, highlighting their relevance in populations at high risk with overweight and obesity. Key considerations as these drugs move forward in development to eventual approval include cost, access and long-term safety. This article is part of the <i>Real-world evidence on the use of GLP1 receptor agonists</i> Special Issue: https://www.drugsincontext.com/special_issues/real-world-evidence-on-the-use-of-glp1-receptor-agonists.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simulated client study on the dispensing practices for narcotic and psychotropic medications in community drug outlets in Ethiopia.","authors":"Tirsit Ketsela Zeleke, Minichil Chanie Worku, Bantayehu Addis Tegegne, Fasil Bayafers Tamene, Gebremariam Wulie Geremew, Samuel Agegnew Wondm, Aschalew Mulatu Tefera, Ayelign Eshete Fitgu, Tekletsadik Tekleslassie Alemayehu, Muluken Adela Alemu, Rahel Belete Abebe, Kale Gubae, Abraham Teym","doi":"10.7573/dic.2025-2-1","DOIUrl":"10.7573/dic.2025-2-1","url":null,"abstract":"<p><strong>Background: </strong>Dispensing prescription-only medications without a valid prescription poses significant public health risks, including inappropriate drug use, adverse drug reactions and medication dependence. Narcotics and psychotropic drugs are particularly vulnerable to misuse. Despite this, limited data exist on the dispensing practices of these medications at community drug retail outlets in Ethiopia. This study aimed to assess the extent and factors of non-prescription dispensing of narcotic and psychotropic medications at community drug retail outlets in Ethiopia.</p><p><strong>Methods: </strong>An observational cross-sectional study was conducted using the simulated client method from June 1, 2023, to September 30, 2023, in Debre Markos town, Ethiopia. Three trained volunteer pharmacy professionals acted as simulated clients. A validated simulated client approach was used to request medications through three different scenarios: symptom-based (depression), direct request by name and request by presenting a medication package.</p><p><strong>Results: </strong>A total of 109 requests were made by the simulated clients at 38 community drug retail outlets during three rounds of observations. The rates of non-prescription dispensing were 28.9% for depression simulation, 60.5% for direct name requests and 81.6% for package-based requests. A total of nine types of narcotic and psychotropic medications were dispensed without prescription, the most common of which were amitriptyline, followed by tramadol, carbamazepine, pethidine and haloperidol.</p><p><strong>Conclusion: </strong>This study revealed a high prevalence of non-prescription dispensing of narcotic and psychotropic medications, particularly in response to assertive client requests. Urgent regulatory measures are needed to ensure adherence to prescription-only policies, especially for frequently dispensed drugs such as amitriptyline, tramadol and chlorpromazine.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy of curcumin plus serratiopeptidase formulation in inflammatory acne: a quasi-experimental study.","authors":"Shakila Junaid, Kiran Naz Khan, Farina Zameer, Muhammad Mudassir, Sadaf Bukhari, Neeta Maheshwary, Muhammad Athar Khan","doi":"10.7573/dic.2025-4-2","DOIUrl":"10.7573/dic.2025-4-2","url":null,"abstract":"<p><strong>Background: </strong>Acne vulgaris is one of the most common dermatological illnesses affecting people worldwide. In Pakistan, approximately 9.4% of the population and between 5% and 16% of young adults are affected by acne vulgaris. Conventional therapies (topical benzoyl peroxide, retinoids, antibiotics and oral isotretinoin) are effective but limited by antibiotic resistance and side effects. Curcumin (a natural anti-inflammatory/antimicrobial from turmeric) and serratiopeptidase (a proteolytic enzyme with anti-inflammatory, anti-oedematous and antibiofilm properties) each show promise in acne treatment. This article evaluates the efficacy of a combined oral curcumin plus serratiopeptidase formulation as an adjunct to inflammatory acne therapy.</p><p><strong>Methods: </strong>Fifty individuals with mild-to-moderate symptoms of inflammatory acne participated in this quasi-experimental study. They were allocated to standard therapy alone (topical regimen: benzoyl peroxide 5% and adapalene 0.1% gel; oral doxycycline 100 mg once daily) or standard therapy plus a daily curcumin (500 mg) + serratiopeptidase (10 mg) supplement (adjunctive therapy). Acne severity was assessed using a visual analogue scale (VAS) and lesion improvement scale at baseline, 1 week and 2 weeks of treatment. Data were analysed with parametric tests after normalization (log transformation), with significance set at <i>p</i><0.05.</p><p><strong>Results: </strong>Baseline characteristics were similar between groups (mean age: 23 years; 66% female). Both groups showed significant improvement in mean VAS (from 7.5 at baseline to 3.1 at 2 weeks; <i>p</i><0.001). The adjunctive therapy group achieved a markedly higher complete/near-complete improvement rate by week 2 (84% <i>versus</i> 28%; <i>p</i><0.001). No serious adverse events occurred.</p><p><strong>Conclusion: </strong>Curcumin plus serratiopeptidase, as an adjunct to standard therapy significantly, accelerated the resolution of inflammatory acne lesions within 2 weeks, with excellent tolerability. This novel combination targets inflammatory pathways and could reduce reliance on prolonged antibiotics. Larger, longer-term studies are recommended to confirm these findings and evaluate effects on relapse and scarring.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of epiretinal membrane traction progression with topical indomethacin treatment: a case report and mini literature review.","authors":"Amedeo Lucente, Andrea Taloni, Federico Fava, Giuseppe Giannaccare","doi":"10.7573/dic.2025-2-4","DOIUrl":"10.7573/dic.2025-2-4","url":null,"abstract":"<p><p>This case report explores the potential of 0.5% indomethacin eye drops (Indo0.5) in preventing the progression of epiretinal membrane traction. A 72-year-old patient with progressive vitreomacular traction was treated with Indo0.5, leading to a significant decrease in intraretinal cyst within 8 months, complete resorption after 16 months and full restoration of the retinal profile after 22 months. A mini literature review highlights the anti-inflammatory effects of indomethacin for various conditions affecting the anterior segment and suggests that the 0.5% concentration may also be effective in managing retinal inflammation. Indo0.5 could be a non-invasive option for slowing epiretinal membrane traction progression, supporting further research to optimize treatment strategies.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report.","authors":"Laura Fabbri, Linda Galvani, Claudio Zamagni","doi":"10.7573/dic.2025-4-3","DOIUrl":"10.7573/dic.2025-4-3","url":null,"abstract":"<p><p>The combination of the immune-checkpoint inhibitor pembrolizumab plus lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, has been approved as standard second-line treatment for patients with recurrent or metastatic endometrial cancer progressed to first-line platinum-based chemotherapy regardless of mismatch repair status and based on the results of the KEYNOTE-775 trial. This article reports on the case of a middle-aged woman with advanced microsatellite stable, p53-mutant endometrial cancer who achieved a meaningful and sustained partial response, with good tolerability, to second-line treatment with pembrolizumab plus lenvatinib. This favourable outcome was compared with efficacy and toxicity data available in the current literature. Pembrolizumab plus lenvatinib can significantly prolong progression-free survival, especially in patients with a negative prognostic molecular profile, who at most can benefit from combining different therapeutic strategies. The heterogeneous treatment-related adverse events landscape should not discourage therapy prescription because most adverse events are easily manageable following simple precautions. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming disease progression in advanced endometrial cancer: a clinical case of sequential therapies.","authors":"Amedeo Cefaliello, Angela Grieco, Roberto Buonaiuto, Valeria Forestieri","doi":"10.7573/dic.2025-4-5","DOIUrl":"10.7573/dic.2025-4-5","url":null,"abstract":"<p><p>Immunotherapy has revolutionized the treatment landscape for solid tumours. Here, we describe the case of a 69-year-old woman with advanced endometrial cancer (EC) who achieved prolonged disease control with immunotherapy. The patient was diagnosed with stage IIIC EC in February 2020 and was treated with carboplatin and paclitaxel, followed by radiotherapy. Relapses occurred in February 2021 (treated with doxorubicin and palliative radiotherapy) and July 2022 (treated with a carboplatin rechallenge). Pembrolizumab and lenvatinib were started in November 2022. Although the initial scan showed progressive disease, restaging 2 months later showed stable disease, which was maintained on pembrolizumab and lenvatinib until progression in October 2024. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases.","authors":"Vanda Salutari","doi":"10.7573/dic.2025-4-4","DOIUrl":"10.7573/dic.2025-4-4","url":null,"abstract":"<p><p>Endometrial cancer (EC) is the most common gynaecological malignancy in developed countries, with advanced-stage disease posing significant therapeutic challenges. Standard treatments, including surgery, radiotherapy and chemotherapy, have limited efficacy in recurrent or metastatic cases, necessitating novel therapeutic approaches. Recent molecular classifications of EC have identified subtypes with distinct prognostic and therapeutic implications, particularly those with high immunogenicity. Immunotherapy, specifically immune-checkpoint inhibitors targeting PD-1/PD-L1, has transformed EC treatment. The combination of pembrolizumab, an anti-PD-1 monoclonal antibody, and lenvatinib, a tyrosine kinase inhibitor (TKI), has demonstrated superior efficacy over chemotherapy in the pivotal KEYNOTE-775 trial, significantly improving progression-free and overall survival in advanced EC. Additionally, dostarlimab has shown promise as a monotherapy for mismatch repair-deficient EC, expanding treatment options. This special series in <i>Drugs in Context</i> explores these advancements through clinical case studies, highlighting real-world applications of immunotherapy and TKIs. Cases illustrate treatment responses, challenges in managing toxicities and the evolving role of molecular profiling in personalizing therapy. As research progresses, integrating immunotherapy and TKIs into routine practice is expected to improve outcomes for patients with advanced EC, offering new hope in a previously limited therapeutic landscape. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report.","authors":"Alessia Lancianese, Elena Maccaroni, Laura Zepponi, Riccardo Giampieri, Rossana Berardi","doi":"10.7573/dic.2025-4-6","DOIUrl":"10.7573/dic.2025-4-6","url":null,"abstract":"<p><p>Advanced endometrial carcinoma (EC) is typically associated with poor prognosis. However, recent advances have revolutionized therapeutic strategies. In patients with microsatellite stable (MSS) advanced EC, pembrolizumab plus lenvatinib have significantly improved overall survival, progression-free survival and response rate compared to standard chemotherapy. We describe the case of a 63-year-old woman with advanced endometrioid adenocarcinoma exhibiting mismatch repair proficiency (pMMR) and MSS who started treatment with pembrolizumab and lenvatinib after failing multiple lines of therapy. The patient had a favourable response, with mild side effects, and continues to receive treatment. Our experience supports pembrolizumab plus lenvatinib as a promising therapeutic option for patients with advanced recurrent EC with pMMR/MSS. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.","authors":"Valentina Tuninetti, Roberta Danese, Amedeo Calvo, Marco Bellero, Lavinia Bianco, Valentina Ariu, Maria Grazia Ruo Redda, Paola Campisi, Alessandra Bianco, Giovanni De Rosa, Massimo Petracchini, Giorgio Valabrega","doi":"10.7573/dic.2025-4-7","DOIUrl":"10.7573/dic.2025-4-7","url":null,"abstract":"<p><p>Until recently, treatment options for patients with recurrent or metastatic endometrial cancer (EC) were limited. First-line treatment is usually based on carboplatin and paclitaxel and there was no standard second-line therapy following platinum failure. However, the introduction of immunotherapy has expanded both first-line and later-line options for EC and made determination of mismatch repair status essential. We describe the case of a 56-year-old woman with deficient mismatch repair/microsatellite instability EC who did not respond to first-line treatment with carboplatin and paclitaxel but had a high response to subsequent immunotherapy with dostarlimab. There was initial pseudoprogression of one target lesion but marked improvement in quality of life. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}